Keyword: Zeltiq

Allergan's efforts to shed its women’s health and infectious disease units aren’t progressing quite as well as CEO Brent Saunders had hoped.

Allergan is targeting a new growth market with its fat-fighting CoolSculpting treatment: Hispanic women.

Allergan’s Zeltiq has been on a tear as of late, but physicians aren’t expecting that trend to last as long as they once did.

Those over-the-top, fad techniques for tackling stubborn body fat? Not cool, Allergan says. And it’s got an alternative.

What’s the best pharma market in the world? According to Allergan CEO Brent Saunders, it’s medical aesthetics.

Halfway through a year Allergan execs have called "pivotal" for Kybella, one analyst describes the product’s launch as “meh.”